

# **UNITED THERAPEUTICS** CORPORATION

Jefferies 2017 Global Healthcare Conference New York City





## Safe Harbor Statement and Non-GAAP Information

### **Remarks today concerning**

United Therapeutics may include forward-looking statements which represent United Therapeutics' expectations or beliefs regarding future events. We caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in United Therapeutics' periodic and other reports filed with the SEC.

### There can be no assurance

that the actual results. events or developments referenced in such forward-looking statements will occur or be realized. United Therapeutics assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements.

### The discussions

during this presentation could include certain financial measures that were not prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Reconciliations of those non-GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in our earnings releases filed with the SEC in Current Reports on Form 8-K for the relevant time period. These reports are available on our website at www.unither.com in the "Investor Relations Financial Information SEC Filings" section.


### This presentation

www.unither.com.

and any related discussions or statements are intended to educate investors about our company. Sometimes that process includes reporting on the progress and results of clinical trials or other developments with respect to our products. This presentation and any related discussions or statements are not intended to promote our products, to suggest that our products are safe and effective for any use other than what is consistent with their FDA-approved labeling, or to provide all available information regarding the products, their risks, or related clinical trial results. Anyone seeking information regarding the use of one of our products should consult the full prescribing information for the product available on our website at

REMODULIN, TYVASO, ORENITRAM and UNITUXIN are registered trademarks of United Therapeutics Corporation. ADCIRCA is a registered trademark of Eli Lilly and Company.








## Transform

## **FOCUSED** on Patients to Deliver Long-term Revenue Growth

### Treating more PAH patients in the US than any other company









## **ADVANCE** Improved Therapeutic Benefit with Our FREEDOM-EV **Combination Therapy Clinical Trial**

## **ORENIPLUS**<sup>TM (1)</sup> for PAH

Extending life by decreasing morbidity/mortality

(1) OreniPlus refers to our effort to expand Orenitram's label to indicate that Orenitram delays morbidity and/or mortality in PAH patients who are on an approved oral background therapy.

FREEDOM-EV **Combination Therapy** 

**ERA or PDE5-I** 






## **ADVANCE** Improved Therapeutic Benefit with Our BEAT Combination Therapy Clinical Trial

## TYSUBERPROST<sup>™(1)</sup> for PAH

Extending life by decreasing morbidity/mortality

 Tysuberprost refers to the combination use of esuberaprost (which has not been approved by FDA) and Tyvaso<sup>®</sup>.




в

## **"CORRIDOR** of Indifference" in PH WHO Group 2 with Our **SOUTHPAW** Clinical Trial

## for PH HFpEF<sup>(2)</sup>

# >50,000 PATIENTS

(1) Orenitram is not FDA approved for Who Group 2 PH patients. (2) PH HFpEF=Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction.




### = Ejection Fraction (%)

## **"CORRIDOR** of Indifference" in PH WHO Group 3 with Our **INCREASE** Clinical Trial

## TYVASO-ILD for PH ILD<sup>[2]</sup>

# >30,000 PATIENTS

(1) Tyvaso is not FDA approved for Who Group 3 PH patients. (2) PH ILD = Pulmonary Hypertension associated with Interstitial Lung Disease.



## **TRANSFORM** the Marketplace to Make More Organs Available for Transplant



people in the US that have end-stage organ disease and may need a heart, kidney or lung transplant

- EX-Vivo Lung Perfusion (EVLP)
- Xenotransplantation
- Engineered and Personalized Lungs




## **TRANSFORM** "Science Fiction" into "Science Fact" with EVLP

To date, EVLP technology has successfully transplanted

# **Solution Solution**

(1) Global figure including all EVLP technologies.





## **XENOTRANSPLANTATION** Transforming the Marketplace to Make More Organs Available for Transplant

## Porcine Xenotransplantation milestones in baboons

Kidney graft > > 8 months

Heart graft > >2 years

Received: 10 October 2016 Revised: 22 December 2016 Accepted: 26 January 2017 DOt 10.1111/sen.12293

ORIGINAL ARTICLE

Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts

Hayato Iwase<sup>1</sup> | Hidetaka Hara<sup>1</sup> | Mohamed Ezzelarab<sup>1</sup> | Tao Li<sup>1,2</sup> Zhongqiang Zhang<sup>1,3</sup> | Bingsi Gao<sup>1,2</sup> | Hong Liu<sup>1,4</sup> | Cassandra Long<sup>1</sup> Yi Wang<sup>2</sup> | Amy Cassano<sup>5</sup> | Edwin Klein<sup>5</sup> | Carol Phelps<sup>6</sup> | David Ayares<sup>6</sup> | Abhinav Humar<sup>1</sup> | Martin Wijkstrom<sup>1</sup> | David K. C. Cooper<sup>1</sup>

Abstract

<sup>1</sup>Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh

PA LISA <sup>4</sup>Center for Kidney Transplantation, Second Attiliated Hospital of the University of South China, Hengyang, Hunan, China <sup>3</sup>Department of General Surperv, Second Xlangya Hospital of the Central South University, Changsha, Hunan, China <sup>4</sup>Department of General Surgery, First

Hospital of Sharxi Medical University, Talyua China <sup>9</sup>Division of Laboratory Animal

Resources, University of Pittsburgh, Pittsburgh, PA, USA \*Revivicor, Blacksburg, VA, USA

David K. C. Gooper, Thomas E. Starzl Transolantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA. HKA. Email: cooperdik@upmc.edu

**Funding Information** NIH, NIAID, Grant/Award Number 821 A1074844, U01 Al068642 and U19 A3090959: NH P40, Grant/Award Number RR012317-09

Background: Genetically engineered pigs could provide a source of kidneys for clinical transplantation. The two longest kidney graft survivals reported to date have been 136 and 310 days, but graft survival >30 days has been unusual until recently. Methods: Donor pigs (n=4) were on an a1,3-galactosyltransferase gene-knockout (GTKO)/human complement regulatory protein (CD46) background (GTKO/CD46). In addition, the pigs were transgenic for at least one human coagulation regulatory pro tein. Two baboons received a kidney from a six-gene pig (GroupA) and two from a three-sene piz (GroupB). Immunosuppressive therapy was identical in all four cases and consisted of anti-thymoglobulin (ATG)+anti-CD20mAb (induction) and anti-CD40 méh+ranamycin+conticosteroids (maintenance) Anti-TNE-# and anti-II-68 méhs were administered to reduce the inflammatory response. Baboons were followed by clinical/laboratory monitoring of immune/coagulation/inflammatory/physiological parameters. At biopsy or euthanasia, the grafts were examined by microscopy Results: The two GroupA baboons remained healthy with normal renal function >7 and >8 months, respectively, but then developed infectious complications. However, no features of a consumptive coasulopathy, eg. thrombocytopenia and reduction of fibringgen, or of a protein-losing nephropathy were observed. There was no evidence of an elicited anti-pig antibody response, and histology of biopsies taken at approximately 4. 6. and 7 months and at necropsy showed no significant abnormalities. In contrast both Group8 baboons developed features of a consumptive coasulopathy and re-

quired euthanasia on day 12. Conclusions: The combination of (i) a graft from a specific six-gene genetically modified pig. (ii) an effective immunosuppressive regimen, and (iii) anti-inflammatory therapy prevented immune injury, a protein-losing nephropathy, and coagulation dysfunction for >7 months. Although the number of experiments is very limited, our impression is that expression of human endothelial protein C recentor (±CDSS) in the graft is important if coagulation dysregulation is to be avoided

WILEY Xenotransplantati




## **TRANSFORM** Transplant Rejection with Engineered and **Personalized Lungs**

Lungs built out of a patient's own lung cells, thus **reducing or** eliminating the risk of:

Transplant rejection

Immunosuppressant therapies





## UNITED THERAPEUTICS **ONE OF THE** MOST MPORTANT COMPANIES FOR HUMAN LONGEVITY

